Polyrizon Ltd. Ordinary Shares (PLRZ)
Stock · NASDAQ · Health Care
$10as of 10/16/2026
Price chart
Active signals
PLRZ Signal Track Record
How signals performed across all stocks →What PLRZ's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Volume Spike | 10 | -12.6% | 40% | September 17, 2026 |
| Bollinger Band Breakdown | 6 | +31.9% | 100% | October 2, 2026 |
| Bollinger Band Breakout | 7 | -15.8% | 14% | August 27, 2026 |
| 200-Day Moving Average TouchActive now | 3 | +9.4% | 100% | July 29, 2026 |
| Any 20-session window (baseline) | +0.4% | 51% |
Computed by MarketWall from daily closing prices since August 18, 2025. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About PLRZ
Polyrizon Ltd., a biotech company, engages in the development of medical device hydrogels in the form of nasal sprays in Israel. The company uses its proprietary technology to develop its products comprising Capture and Contain, a barrier against a range of allergen particulates and viruses; and Trap and Target for nasal delivery of active pharmaceutical ingredients. It also develops PL-14, a nasal allergies blocker;…
- Sector
- Health Care
- Industry
- Medical/Dental Instruments
- Employees
- 2
- Website
- polyrizon-biotech.com/
Fundamentals
- 1-day range
- $9$10
- Market cap
- $21.51M
- P/E (trailing)
- —
- P/E (forward)
- —
- EPS (trailing)
- $-5.64
- Dividend yield
- —
- Beta
- 0.56
- Avg. volume
- 61.6K
Polyrizon Ltd. Ordinary Shares Competitors
Chosen by industry and closest market cap.
- PLRZPolyrizon Ltd. Ordinary Shares$10▼ 0.10%Market cap $21.51MP/E —$2.88$18.2
- RVPRetractable Technologies Inc. Common Stock$0.58▼ 1.69%Market cap $20.27MP/E —$0.5844$1.14
- CTSOCytosorbents Corporation Common Stock$4.11▲ 34.31%Market cap $25.05MP/E —$2.96$18.8
- CNSYCerenome Inc. Common Stock$1.7▼ 9.57%Market cap $26.57MP/E —$1.49$4.16
- ADGMAdagio Medical Holdings Inc Common Stock$0.099▼ 3.88%Market cap $16.26MP/E —$0.083$2.02
- MDAIWSpectral AI Inc. Warrants$0.445▲ 8.54%Market cap $15.91MP/E —$0.355$1.01
- OSRHOSR Health Inc. Common Stock$0.226▲ 13.00%Market cap $15.32MP/E 12.44$0.075$0.9078
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| PLRZ Polyrizon Ltd. Ordinary Shares | $21.51M | — | $10 | ▼ 0.10% | $2.88$18.2 |
| RVP Retractable Technologies Inc. Common Stock | $20.27M | — | $0.58 | ▼ 1.69% | $0.5844$1.14 |
| CTSO Cytosorbents Corporation Common Stock | $25.05M | — | $4.11 | ▲ 34.31% | $2.96$18.8 |
| CNSY Cerenome Inc. Common Stock | $26.57M | — | $1.7 | ▼ 9.57% | $1.49$4.16 |
| ADGM Adagio Medical Holdings Inc Common Stock | $16.26M | — | $0.099 | ▼ 3.88% | $0.083$2.02 |
| MDAIW Spectral AI Inc. Warrants | $15.91M | — | $0.445 | ▲ 8.54% | $0.355$1.01 |
| OSRH OSR Health Inc. Common Stock | $15.32M | 12.44 | $0.226 | ▲ 13.00% | $0.075$0.9078 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
- Polyrizon Files New US Divisional Patent Application With USPTO, Further Expanding Its IP Portfolio Relating To Proprietary Mucoadhesive Technologybenzinga · 10/5/2026
- Polyrizon Files for U.S. Patent Application to Expand IP Moat Around Intranasal Drug-Delivery PlatformYahoo · 10/5/2026
- Polyrizon Files New US Divisional Patent Application With USPTO, Further Expanding Its IP Portfolio Relating To Proprietary Mucoadhesive TechnologyBenzinga · 10/5/2026
- Polyrizon Enrolls First Patient in U.S. Clinical Study of NASARIX (PL-14) Allergy BlockerYahoo · 9/22/2026
- Polyrizon Enrolls First Patient In U.S. NASARIX Allergy Blocker Trial, Entering Clinical StageBenzinga · 9/22/2026
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 5, 2026
Polyrizon Files New US Patent Application for Mucoadhesive Tech
Polyrizon Ltd. filed a new U.S. divisional patent application with the USPTO, adding to its mucoadhesive technology portfolio. The filing expands the company’s intellectual property base and could support future product development. The move may strengthen its competitive position in the biopharmaceutical market. The stock is trading near its 13‑touch support level of $11.06.
Polyrizon Files New US Patent Application for Mucoadhesive Tech. Polyrizon Ltd. filed a new U.S. divisional patent application with the USPTO, adding to its mucoadhesive technology portfolio. The filing expands the company’s intellectual property base and could support future product development. The move may strengthen its competitive position in the biopharmaceutical market. The stock is trading near its 13‑touch support level of $11.06.